Session Information

Sponsored Seminar

[ILS-SA-40] Lunch Seminar 40: Recent managements of retinitis pigmentosa
Go back
print
Day
Apr 05 (Sat)
Time
12:15 - 13:15
Room
Room 9 - Tokyo International Forum 6F G602
Sponsor
R-Tech Ueno, Ltd
Topic
Retina, Vitreous body
Chair/Coordinator
Chair)Yozo Miyake
Description
Epidemiologic researches of RP patients with mid to late stages are necessary to develop appropriate clinical endpoints for coming new treatments. Although visual acuity is the most common clinical endpoint, it takes long time to show the prevention of loss of vision in the clinical trial through new therapies. To develop the new therapies for RP, clinician scientists who are familiar with not only basic and clinical researches but also applied research will play important roles. In this seminar, three clinician scientists will present the managements of recent RP treatments: clinical endpoints for RP study, gene therapy, and iPS cell therapy.

ILS-SA-40 / 

Retina, Vitreous body

Evaluation of visual function in retinitis pigmentosa

Shuichi Yamamoto

Evaluation of visual function in  retinitis pigmentosa

ILS-SA-40 / 

Retina, Vitreous body

Phase I Clinical Trial of Neuroprotective Gene Therapy for Patients with Retinitis Pigmentosa

Yasuhiro Ikeda

Phase I Clinical Trial of Neuroprotective Gene Therapy for Patients with Retinitis Pigmentosa

ILS-SA-40 / 

Retina, Vitreous body

Application of iPS cells for retinal diseases

Masayo Takahashi

Application of iPS cells for retinal diseases

Go back